Acrivon Therapeutics Q4/FY2025 net loss $19M/$77.9M; cash $118.6M; ACR-368 52% cORR in serous EC

Acrivon Therapeutics, Inc.

Net loss Q4 $19.0M, FY $77.9M; cash and securities $118.6M expected to fund into Q2 2027.
ACR-368 Phase 2b showed 52% confirmed ORR in serous endometrial cancer; Arm 3 enrolling, Arm 4 to start H1 2026.
Completed exploratory Arm 2 (ACR-368 + ULDG) in biomarker-negative EC; objectives met with favorable tolerability.
ACR-2316 Phase 1 data shows tumor shrinkage in SCLC and squamous NSCLC; IND for ACR-6840 planned Q4 2026.
Launched wholly-owned CLIA lab for companion diagnostic development.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acrivon Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively..

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively.
Result: reported results

Exact text from the filing

Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively.

View on SEC.gov

Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-115139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.